Stock Scorecard
Stock Summary for Takeda Pharmaceutical Company (TAK) - $15.10 as of 9/12/2025 9:29:04 PM EST
Total Score
13 out of 30
Safety Score
55 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for TAK
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for TAK
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for TAK
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for TAK
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for TAK (55 out of 100)
| Stock Price Rating (Max of 10) | 6 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 10 |
| Book Value to Price (Max of 10) | 10 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 6 |
| Operating Margin (Max of 10) | 4 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 2 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for TAK
Financial Details for TAK
Company Overview |
|
|---|---|
| Ticker | TAK |
| Company Name | Takeda Pharmaceutical Company |
| Country | USA |
| Description | Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan. |
| Sector Name | HEALTHCARE |
| Industry Name | DRUG MANUFACTURERS - SPECIALTY & GENERIC |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 10/30/2025 |
Stock Price History |
|
| Last Day Price | 15.10 |
| Price 4 Years Ago | 11.70 |
| Last Day Price Updated | 9/12/2025 9:29:04 PM EST |
| Last Day Volume | 2,820,519 |
| Average Daily Volume | 3,875,136 |
| 52-Week High | 15.69 |
| 52-Week Low | 12.51 |
| Last Price to 52 Week Low | 20.70% |
Valuation Measures |
|
| Trailing PE | 52.72 |
| Industry PE | 93.47 |
| Sector PE | 40.86 |
| 5-Year Average PE | 0.28 |
| Free Cash Flow Ratio | 0.14 |
| Industry Free Cash Flow Ratio | 13.26 |
| Sector Free Cash Flow Ratio | 29.37 |
| Current Ratio Most Recent Quarter | 1.16 |
| Total Cash Per Share | 110.82 |
| Book Value Per Share Most Recent Quarter | 4,395.19 |
| Price to Book Ratio | 1.04 |
| Industry Price to Book Ratio | 12.21 |
| Sector Price to Book Ratio | 32.27 |
| Price to Sales Ratio Twelve Trailing Months | 0.01 |
| Industry Price to Sales Ratio Twelve Trailing Months | 2.88 |
| Sector Price to Sales Ratio Twelve Trailing Months | 19.72 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 3,158,220,000 |
| Market Capitalization | 47,689,122,000 |
| Institutional Ownership | 2.50% |
Dividends |
|
| Ex-Dividend Date | 3/31/2025 |
| Previous Dividend Amount | 0.3261 |
| Current Dividend Amount | 0.3390 |
| Total Years Dividend Increasing | 0 |
| Trailing Annual Dividend Rate | 0.67 |
| Trailing Annual Dividend Yield | 4.36% |
| Forward Annual Dividend Rate | 0.68 |
| Forward Annual Dividend Yield | 4.44% |
| 5-Year Dividend Payments Count | 10 |
| 3-Year Average Dividend Yield | 4.78% |
| 5-Year Average Dividend Yield | 5.26% |
| 1-Year Dividend Growth Rate Percentage | 9.66% |
| 3-Year Dividend Growth Rate Percentage | 4.72% |
| 5-Year Dividend Growth Rate Percentage | -4.16% |
| All-Time Dividend Growth Rate Percentage | -3.37% |
| Dividend Payout Ratio | 229.34% |
Income Statement |
|
| Quarterly Earnings Growth YOY | 30.50% |
| Annual Earnings Growth | -25.08% |
| Reported EPS 12 Trailing Months | 0.29 |
| Reported EPS Past Year | 151.00 |
| Reported EPS Prior Year | 29.08 |
| Net Income Twelve Trailing Months | 136,878,000,000 |
| Net Income Past Year | 107,928,000,000 |
| Net Income Prior Year | 144,067,000,000 |
| Quarterly Revenue Growth YOY | -8.40% |
| 5-Year Revenue Growth | 6.84% |
| Operating Margin Twelve Trailing Months | 16.90% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 350,008,000,000 |
| Total Cash Past Year | 385,113,000,000 |
| Total Cash Prior Year | 457,800,000,000 |
| Net Cash Position Most Recent Quarter | -3,784,791,000,000 |
| Net Cash Position Past Year | -3,581,213,000,000 |
| Long Term Debt Past Year | 3,966,326,000,000 |
| Long Term Debt Prior Year | 4,476,501,000,000 |
| Total Debt Most Recent Quarter | 4,134,799,000,000 |
| Equity to Debt Ratio Past Year | 0.64 |
| Equity to Debt Ratio Most Recent Quarter | 0.62 |
| Total Stockholder Equity Past Year | 6,935,084,000,000 |
| Total Stockholder Equity Prior Year | 7,273,264,000,000 |
| Total Stockholder Equity Most Recent Quarter | 6,865,259,000,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 883,879,000,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 279.87 |
| Free Cash Flow Past Year | 856,387,000,000 |
| Free Cash Flow Prior Year | 235,614,000,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.16 |
| MACD Signal | 0.15 |
| 20-Day Bollinger Lower Band | 14.01 |
| 20-Day Bollinger Middle Band | 14.86 |
| 20-Day Bollinger Upper Band | 15.71 |
| Beta | 0.27 |
| RSI | 53.23 |
| 50-Day SMA | 14.11 |
| 150-Day SMA | 13.85 |
| 200-Day SMA | 13.45 |
System |
|
| Modified | 9/11/2025 11:03:45 AM EST |